The “Mom Rule” is Caris Life Sciences’ guiding principle, emphasizing the importance of treating every patient as if they were your own mother. Driven by our commitment to helping patients, we are paving the way for personalized care and helping improve outcomes. Learn more about our culture of compassion and scientific excellence from Caris President David Spetzler: https://lnkd.in/gA4XqwnT
Caris Life Sciences
Biotechnology Research
Irving, Texas 58,243 followers
Fulfilling the promise of precision medicine through quality and innovation.
About us
Caris Life Sciences® (Caris) is the leading next-generation TechBio company and precision medicine pioneer that is actively developing and delivering innovative solutions to revolutionize healthcare and improve the human condition. Through comprehensive molecular profiling (Whole Exome and Whole Transcriptome Sequencing) and the application of advanced artificial intelligence (AI) and machine learning algorithms, Caris has created the large-scale, clinico-genomic database and computing capability needed to analyze and unravel the molecular complexity of disease. This convergence of sequencing power, big data and AI technologies provides an unmatched platform to deliver the next-generation of precision medicine tools for early detection, diagnosis, monitoring, therapy selection and drug development. Headquartered in Irving, Texas, Caris has offices in Phoenix, New York, Tokyo, Japan and Basel, Switzerland. Caris or its distributor partners provide services in the U.S., Europe, Asia and other international markets.
- Website
-
https://www.carislifesciences.com
External link for Caris Life Sciences
- Industry
- Biotechnology Research
- Company size
- 1,001-5,000 employees
- Headquarters
- Irving, Texas
- Type
- Privately Held
- Founded
- 1996
- Specialties
- Biotechnology, Molecular Profiling, Genomics, Personalized Medicine, Diagnostics, Theranostics, Panomics, Precision Medicine, and Comprehensive Genomic Profiling
Locations
-
Primary
750 W John Carpenter Fwy
Irving, Texas 75039, US
-
4610 S 44th Pl
Phoenix, Arizona 85040, US
-
St. Jakobsstrasse
199, 4052 Basel, CH
Employees at Caris Life Sciences
Updates
-
Meet Jeanine Cervoni, a breast cancer survivor and advocate for awareness. With the support of Caris Life Sciences' innovative testing, she gained a deeper understanding of her cancer and made informed treatment choices. Her journey highlights the importance of personalized care. We observe Breast Cancer Awareness Month this October and advocate for tailored treatment solutions. Learn more: https://lnkd.in/gWN_f5MG #BreastCancerAwarenessMonth #PrecisionMedicine #MolecularProfiling
-
Can RNA transcriptional subtyping (TS) help predict outcomes in #pancreaticcancer? A study of more than 8,700 patients shows that the strongly basal (SB) subtype is a strong independent predictor of worse outcome irrespective of mutant KRAS allele & chemotherapy regimen. TS may be useful for prognostication in clinical care and risk stratification in clinical trials. Learn more: https://lnkd.in/gM76nUxy #CancerResearch #PrecisionMedicine
-
Discover the future of cancer care during the College of American Pathologists (CAP) Annual Meeting. Stop by booth 234 to connect with Caris and explore advanced molecular profiling solutions. Take advantage of the opportunity to network during #CAP24.
-
Discover the power of Caris Assure! Our liquid biopsy assay, Caris Assure, provides unparalleled molecular insights from a minimally invasive blood sample. With its pan-cancer coverage, this revolutionary assay empowers clinicians to make targeted treatment decisions confidently. Don't wait any longer—discover how Caris Assure can help: https://lnkd.in/gZm92Zdg #LiquidBiopsy #PrecisionMedicine #CarisAssure
-
Join Caris Chief Scientific Officer Milan Radovich, PhD, for a panel discussion on the role of high-quality linked clinical and multiomics real-world data in accelerating drug development at every stage. Register Now: https://lnkd.in/e3dgCQNw
TOMORROW: Join speakers from Caris Life Sciences, University of Pennsylvania, and Flatiron Health on October 10th for a discussion on the pivotal role that high-quality linked clinical and multiomics #RWD plays in accelerating all stages of drug development to maximize the success of novel therapeutics. Register today: http://spkl.io/6047fzhnc
-
Caris Biopharma Solutions' comprehensive and integrated suite of biopharma services delivers value across your entire program life cycle—from development through launch and beyond. Discover more: https://lnkd.in/g_T42d33 #BiopharmaSolution #BioTech #PrecisionMedicine
-
UVA Cancer Center joins Caris’ extensive network of leading cancer institutions and research consortia committed to improving patient outcomes through innovations in precision medicine. “We’re pleased to welcome UVA Cancer Center into the Caris Precision Oncology Alliance,” said George Sledge, Jr., MD, EVP and Chief Medical Officer of Caris. “We look forward to collaborating with their team of investigators on our shared mission of reducing the burden of cancer through research, education, patient care and community outreach.” Learn more: https://lnkd.in/gEt3HUDp
-
The availability of next-generation sequencing (NGS) technology helps open new avenues for cancer treatment. By incorporating insights from RNA expression profiling, we can optimize therapies to help meet the unique needs of each patient, enhancing the effectiveness of immunotherapy. Caris Life Sciences contributors Ari VanderWalde, MD, MPH, and Andrew Elliott, Ph.D., provide exciting insights into this collaborative research.
-
Subsets of colorectal cancer patients display different responses to targeted therapies. In collaboration with Caris Life Sciences, investigators at The University of Texas MD Anderson Cancer Center and their co-authors show how Consensus Molecular Subtyping can help identify patients most likely to experience clinical benefit from immune checkpoint blockade and anti-EGFR therapies. Learn more: https://lnkd.in/gfeS4t87 #CancerResearch #PrecisionMedicine #MolecularProfiling